Skin cancer as a contraindication to organ transplantation

American Journal of Transplantation

Volumn 5, Issue 9, 2005, Pages 2079-2084

  Otley, Clark C ^a   Hirose, Ryutaro ^b   Salasche, Stuart J ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Basal cell carcinoma; Immunosuppression; Melanoma; Metastasis; Organ transplant; Skin cancer; Squamous cell carcinoma; Transplantation

Indexed keywords

ADNEXA DISEASE; ALLOGRAFT; BASAL CELL CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; DERMATOFIBROSARCOMA PROTUBERANS; FIBROXANTHOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; MELANOMA; METASTASIS; ORGAN TRANSPLANTATION; PAGET SKIN DISEASE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SEBACEOUS CARCINOMA; SHORT SURVEY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SWEAT GLAND CARCINOMA; TREATMENT CONTRAINDICATION;

CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELANOMA; ORGAN TRANSPLANTATION; PROGNOSIS; RISK; SKIN NEOPLASMS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 27844498802     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01036.x     Document Type: Short Survey

References (27)

1. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55: 742-747.
2. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-1530.
3. Chuang TY, Popescu NA, Su WPD, Chute CG. Squamous cell carcinoma: a population-based incidence study in Rochester, Minn. Arch Dermatol 1990; 126: 185-188.
4. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17.
5. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-990.
6. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26: 467-484.
7. Martinez JC, Otley CC, Stasko T et al. Transplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139: 301-306.
8. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
9. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
10. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61: 274-278.
11. Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999; 68: 1717-1721.
12. O'Connor WJ, Brodland DG. Merkel cell carcinoma. Dermatol Surg 1996; 22: 262-267.
13. Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope 1992; 102: 244-249.
14. Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 60: 1485-1491.
15. Hafner J, Künzi W, Weinreich T. Malignant fibrous histiocytoma and atypical fibroxanthoma in renal transplant recipients. Dermatology 1999; 198: 29-32.
16. Rizzardi C, Angiero F, Melato M. Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin. Anticancer Res 2003; 23: 1847-1851.
17. Davis JL, Randle HW, Zalla MJ, Roenigk RK, Brodland DG. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg 1997; 23: 105-110.
18. Ratner D, Thomas CO, Johnson TM et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997; 37: 600-613.
19. Muqit MMK, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye 2004; 18: 49-53.
20. Bassetto F, Baraziol R, Sottosanti MV, Scarpa C, Montesco M. Biological behavior of the sebaceous carcinoma of the head. Dermatol Surg 2004; 30: 472-476.
21. Wick MR, Goellner JR, Wolfe JT III, Su WPD. Adnexal carcinomas of the skin: I. Eccrine carcinomas. Cancer 1985; 56: 1147-1162.
22. Snow S, Madjar DD, Hardy S et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg 2001; 27: 401-408.
23. O'Connor WJ, Lim KK, Zalla MJ et al. Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 2003; 27: 723-727.
24. Pierie JPEN, Choudry U, Muzikansky A, Finkelstein DM, Ott MJ. Prognosis and management of extramammary Paget's disease and the association with secondary malignancies. J Am Coll Surg 2003; 196: 45-50.
25. Kahan BD, Knight R, Schoenberg L et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35(Suppl 3A): 25S-34S.
26. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449.
27. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762.